SCTbio
- Company typePrivate
- Founded2021
- HeadquartersPrague, Czechia
- Headcount—
- GTM typeB2B
- OfferingServices
SCTbio firmographics
Firmographics- Name
- SCTbio
- Legal name
- SCT Cell Manufacturing s.r.o.
- Website
- https://sctbio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Ownership category
- akta.pro rank
SCTbio industry classification
Industry- Product category
- Cell and Gene Therapy CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy CDMO (HLAGABAD)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)
Keywords
Where SCTbio is headquartered
LocationHeadquarters
- HQ city
- Prague
- HQ country
- Czechia
- HQ region
- Europe
Offices2 records
Markets served
SCTbio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Manufacturing Services: SCTbio provides GMP manufacturing services to biotech and pharmaceutical companies developing cell and gene therapies. Revenue is generated through service contracts for clinical and commercial manufacturing of cell therapies and viral vectors.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
SCTbio product offering
Product offeringCore offering
SCTbio is a Contract Development and Manufacturing Organization (CDMO) providing integrated GMP manufacturing services for cell and gene therapies. The company operates from a 2,000 sqm facility in Prague, Czech Republic, offering cGMP manufacturing, analytical development, process development, logistics and apheresis collection, procurement and warehouse management, and quality/regulatory/QP services for clinical and commercial-stage cell therapies and lentiviral/gammaretroviral vectors.
Product overview
SCTbio is a Contract Development and Manufacturing Organization (CDMO) providing integrated GMP manufacturing services for cell and gene therapies. The company operates from a 2,000 sqm facility in Prague, Czech Republic, offering a comprehensive suite of services including cGMP manufacturing and quality control, analytical development, process development, logistics and apheresis collection (with 150 qualified sites globally), procurement and warehouse management, and quality/regulatory support. Core manufacturing capabilities include lentiviral and gammaretroviral vector production, cell therapy manufacturing (including CAR-T and dendritic cell therapeutics), and fill & finish services. The company is supported by PPF Group and serves as a strategic partner for biotech companies developing advanced therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- cGMP Manufacturing & Quality Control Clinical and commercial manufacturing capabilities for cell and gene therapies, including fill & finish operations, quality control testing, and QA/QP release services. Targeted at biotech and pharmaceutical companies developing advanced therapies.
- Analytical Development Comprehensive analytical testing services including method development and validation for cell therapy products. Aimed at biotech developers requiring analytical support across the development lifecycle.
- Process Development Development and optimization of manufacturing processes for cell-based therapies and viral vectors. Targeted at therapeutic developers needing to scale and optimize manufacturing processes.
- Logistics Services & Apheresis Collection Global logistics network with 150 qualified and regularly monitored apheresis centers in Europe and USA, providing cell collection and temperature-controlled supply chain management for cell therapy products.
- Procurement & Warehouse Management Supply chain management services including raw material procurement and storage for cell and gene therapy manufacturing operations.
- Quality & Regulatory Support & QP Services
Quantifiable outcome
- 150 qualified apheresis collection sites across Europe and USA
Companies that use SCTbio
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles1 record
SCTbio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
SCTbio partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship and core.
- FortreaflagshipStrategic collaboration to streamline clinical trial logistics with GMP manufacturing readiness. Combines Fortrea's global clinical research reach with SCTbio's expertise in cell therapy, viral vectors, and apheresis to create synchronized solutions across the development lifecycle.
- Oslo University HospitalcorePartnership to accelerate CAR-T innovation in solid tumors, leveraging hospital's clinical research capabilities with SCTbio's manufacturing expertise.
- CCRM NordiccoreStrategic partnership to accelerate advanced therapy development, combining expertise in cell therapy manufacturing and regional development capabilities.
- Cyto-carecoreCollaboration to improve cell therapy cryopreservation and logistics capabilities in Europe, combining Cyto-care's cryopreservation expertise with SCTbio's logistics network.
- OrgenesiscoreCollaboration for production of lentivirus vectors to support Orgenesis' point-of-care cell and gene therapy customers in the EU, including CAR-T applications.
Scale indicators3 records
Recent moves10 records
Expansion highlights5 records
SCTbio competitors and assessment
Company assessmentDirect peers
- Minaris Regenerative Medicine: Specialized cell therapy CDMO offering GMP manufacturing of cell-based therapies. Directly competes with SCTbio in autologous and allogeneic cell therapy manufacturing.
- Lonza Group: One of the world's largest CDMOs with significant cell and gene therapy manufacturing capabilities across multiple geographies. Competes directly with SCTbio for outsourced cell therapy and viral vector manufacturing clients.
- Catalent: Major CDMO with cell therapy manufacturing services including viral vector production and fill-finish capabilities. A direct competitor in the cell and gene therapy CDMO space.
- RoslinCT: Cell therapy CDMO focused on GMP manufacturing of cell-based therapies for clinical and commercial use. A focused peer with similar product offering and customer base.
- CCRM: Canadian-based organization offering cell and gene therapy development and manufacturing services. Recent partnership with SCTbio (CCRM Nordic) highlights operational overlap in advanced therapy manufacturing.
- WuXi Advanced Therapies: Cell and gene therapy CDMO unit of WuXi AppTec offering viral vector and cell therapy manufacturing services. Competes with SCTbio for biotech clients globally.
- AGC Biologics: CDMO specializing in cell and gene therapies, viral vectors, and biologics manufacturing. Directly comparable to SCTbio in target market and service offerings.
Broad incumbents
- Charles River Laboratories: Large CRO/CDMO offering cell and gene therapy manufacturing and testing services as part of a broader discovery-to-manufacturing portfolio.
- Thermo Fisher Scientific (Patheon): Global life sciences and CDMO conglomerate with cell and gene therapy manufacturing services within a much broader portfolio. Overlaps with SCTbio on cell therapy and viral vector CDMO offerings.
Regional players
- Cell and Gene Therapy Catapult: UK-based cell and gene therapy manufacturing center of excellence with GMP facilities. Comparable offering though primarily serving UK and European clients with different geographic focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
SCTbio social profiles
Digital presenceSCTbio compliance and trust
Trust signalCompliance3 records
SCTbio financial estimates
Financial estimateRevenue estimate
Valuation estimate
SCTbio leadership team
Management profileNumber of profiles
Profiles2 records
SCTbio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SCTbio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SCTbio
What does SCTbio do?
SCTbio is a Contract Development and Manufacturing Organization (CDMO) providing integrated GMP manufacturing services for cell and gene therapies. The company operates from a 2,000 sqm facility in Prague, Czech Republic, offering cGMP manufacturing, analytical development, process development, logistics and apheresis collection, procurement and warehouse management, and quality/regulatory/QP services for clinical and commercial-stage cell therapies and lentiviral/gammaretroviral vectors.
Is SCTbio a public or private company?
SCTbio is a private company. It is classified as corporate owned and is currently operating.
When was SCTbio founded?
SCTbio was founded in 2021.
Where is SCTbio based?
SCTbio is headquartered in Prague, Czechia, in the Europe region.
How does SCTbio make money?
One revenue line is on record: contract Manufacturing Services.
Who are SCTbio's main competitors?
Direct peers on record are Minaris Regenerative Medicine, Lonza Group, Catalent, RoslinCT, CCRM, WuXi Advanced Therapies and AGC Biologics. Broad incumbents are Charles River Laboratories and Thermo Fisher Scientific (Patheon). Cell and Gene Therapy Catapult is listed as a regional player.
Does SCTbio have an API?
No public API is recorded for SCTbio.
What industry is SCTbio in?
SCTbio's product category is Cell and Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 8731.